Effets indésirables des nouvelles approches thérapeutiques en oncologie thoracique [Adverse effects of new therapeutic approaches in thoracic oncology]
Gespeichert in:
| Titel: | Effets indésirables des nouvelles approches thérapeutiques en oncologie thoracique [Adverse effects of new therapeutic approaches in thoracic oncology] |
|---|---|
| Autoren: | Sammya, A., Normand, C., Desbaillets, N., Coskun, M., Goudemant, C., Mosimann, V., Ferahta, N., Christofis, M., Serena, A., Nikolopoulou, A., Abdelhamid, K., Stamatiou, A., Nguyen-Ngoc, T., Bouchaab, H., Fleury, M., Obeid, M., Peters, S., Mederos, N. |
| Quelle: | Revue medicale suisse, vol. 21, no. 918, pp. 1023-1030 |
| Verlagsinformationen: | 2025. |
| Publikationsjahr: | 2025 |
| Schlagwörter: | Humans, Immune Checkpoint Inhibitors/adverse effects, Immune Checkpoint Inhibitors/administration & dosage, Lung Neoplasms/drug therapy, Lung Neoplasms/therapy, Immunoconjugates/adverse effects, Immunoconjugates/administration & dosage, Molecular Targeted Therapy/adverse effects, Molecular Targeted Therapy/methods, Antineoplastic Agents/adverse effects |
| Beschreibung: | The rapid evolution of oncological treatments in patients with lung cancer has led to the emergence of targeted therapies (TT), immune checkpoint inhibitors (ICI), and antibody-drug conjugates (ADC), which are significantly transforming the management of cancer. However, these advances are associated with complex adverse effects that affect multiple organ systems. This review explores the etiopathogenic mechanisms underlying therapy-related toxicity and describes the major adverse effects: immune-related toxicity of ICIs, "on-target" and "off-target" effects of TTs, and systemic toxicity of ADCs. Systemic toxicities are discussed, with a focus on monitoring strategies and management approaches. A multidisciplinary approach is critical to optimize therapeutic efficacy while minimizing toxicity. |
| Publikationsart: | Review |
| Dateibeschreibung: | application/pdf |
| Sprache: | French |
| Zugangs-URL: | http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_CCB0F1473EB76 https://serval.unil.ch/resource/serval:BIB_CCB0F1473EB7.P001/REF.pdf https://serval.unil.ch/notice/serval:BIB_CCB0F1473EB7 |
| Rights: | CC BY NC ND |
| Dokumentencode: | edsair.od......1900..436a427cf253f5280c84af33ef93d801 |
| Datenbank: | OpenAIRE |
Nájsť tento článok vo Web of Science | Abstract: | The rapid evolution of oncological treatments in patients with lung cancer has led to the emergence of targeted therapies (TT), immune checkpoint inhibitors (ICI), and antibody-drug conjugates (ADC), which are significantly transforming the management of cancer. However, these advances are associated with complex adverse effects that affect multiple organ systems. This review explores the etiopathogenic mechanisms underlying therapy-related toxicity and describes the major adverse effects: immune-related toxicity of ICIs, "on-target" and "off-target" effects of TTs, and systemic toxicity of ADCs. Systemic toxicities are discussed, with a focus on monitoring strategies and management approaches. A multidisciplinary approach is critical to optimize therapeutic efficacy while minimizing toxicity. |
|---|